Parabase Genomics
Pioneering the future of newborn genetic diagnostics with rapid, comprehensive testing for over 500 genes within 10 days using a simple dried blood spot.
Pioneering the future of newborn genetic diagnostics with rapid, comprehensive testing for over 500 genes within 10 days using a simple dried blood spot.
Parabase Genomics is a biotechnology startup pioneering the future of newborn genetic diagnostics with its NewbornDx™ test. Founded in 2009, the company is committed to improving the diagnosis and treatment of genetic disorders in newborns and children. The NewbornDx™ test offers rapid, comprehensive testing for over 500 genes within 10 days using a simple dried blood spot, enabling physicians to obtain an accurate molecular profile without the need to rely on severe phenotypes. The company received a $2.00M Series B investment on November 4, 2014, with Walnut Venture Associates and SXE Ventures participating as investors. Parabase Genomics operates within the Biotechnology and Health Care industries, aiming to make a significant impact in the field of genetic diagnostics for newborns.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $2.00M | 2 |
|
04 Nov 2014 |
| Grant | Unknown | - | 01 Jan 2013 | |
| Seed Round | $970.00K | - | 20 Jul 2012 |
No recent news or press coverage available for Parabase Genomics.
We care about your data, and we'd love to use cookies make your experience better.